Fig. 2From: Safety and efficacy of elagolix (with and without add-back therapy) for the treatment of heavy menstrual bleeding associated with uterine leiomyomas: a systematic review and meta-analysisForest plot comparing the primary outcome (women with MBV ≤ 80 ml/cycle and ≥ 50% reduction from baseline) across treatmentsBack to article page